Prolonged Postprandial Increment in Triglycerides and Decreased Postprandial Response of Very Low Density Lipoproteins in Type 2 Diabetics following an Oral Lipid Load

Weber, Patricia A.; Schrezenmeir, Jürgen; Fenselau, S.; Ausieker, S.; Probst, R.; Zuchhold, H. D.; Prellwitz, W.; Beyer, J.

doi:10.1111/j.1749-6632.1993.tb35722.x

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impact of glucagon on fibrinolysis Henkel et al 331 Fasting t-PA (ng/ml) 8 Many studies have addressed the fact that the postprandial phase constitutes a state of enhanced atherosclerotic risk in diabetes and prediabetes, where many metabolic parameters show altered postprandial curves in comparison with individuals with NGT [20,21]. In some studies the postprandial hypertriglyceridemia of type 2 diabetes has been observed to increase PAI-1 levels [18].…”

Section: Discussionmentioning

confidence: 98%

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis

Henkel

Gallo²,

Siegert³

et al. 2007

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Glucagon plays an important role in postprandial hyperglycemia in type 2 diabetes (T2DM), and coexists with insulin resistance and impaired fibrinolysis. We analyzed the response of plasminogen activator inhibitor-1 (PAI-1) to a lipid-glucose-protein test and the relationship between glucagon and PAI-1, tissue plasminogen activator (t-PA) and PAI-1/t-PA in 26 men with normal glucose tolerance (NGT), nine with impaired glucose tolerance (IGT) and 12 with T2DM. Fasting and postprandial PAI-1 were higher in T2DM versus NGT (P < 0.05). In univariate analysis in NGT, fasting and area under the curve (AUC) PAI-1 showed a strong relationship with fasting (P = 0.003, P = 0.006) and postprandial (P = 0.041, P = 0.045) glucagon, t-PA with fasting glucagon (P = 0.014), and PAI-1/t-PA with fasting (P = 0.047) and AUC glucagon (P = 0.017). In IGT fasting, AUC PAI-1 and PAI-1/t-PA were associated with AUC glucagon (P = 0.035, P = 0.032, P = 0.023). In NGT with the fasting metabolic parameters and insulin resistance as independent variables, fasting glucagon remained an independent covariate for PAI-1 and PAI-1/t-PA. In another model, postprandial glucagon was independently associated with PAI-1/t-PA in NGT (P < 0.05). Besides the already established determinants, we found an independent association between glucagon and fibrinolysis in NGT. Further studies are needed to identify the link between glucagon, insulin resistance and hemostasis.

show abstract

Section: Discussionmentioning

confidence: 98%

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis

Henkel

Gallo²,

Siegert³

et al. 2007

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Increased elimination velocity of chylomicrons is accompanied by increased lipoprotein lipase (LPL) and more pronounced by increased hepatic lipase activity (HL) . In advanced stages of the metabolic syndrome when diabetes mellitus (and insulin deficiency) is overt, triglyceride clearance is reduced (Weber et al, 1993). Postprandial lipemia comprises particles both of exogenous and endogenous origin.…”

Section: Characteristics Of the Metabolic Syndromementioning

confidence: 99%

Treatment of dyslipoproteinemia in the metabolic syndrome

Steinmetz

Fenselau²,

Schrezenmeir³

2001

Exp Clin Endocrinol Diabetes

Self Cite

View full text Add to dashboard Cite

The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk to develop cardiovascular disease. The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity. To decrease the risk of cardiovascular disease events decreasing body weight by ingesting a healthy diet, increasing physical activity, cessation of smoking and managing dyslipidemia are recommended. Pharmacological treatment of dyslipidemia is based on different drug classes. For LDL-cholesterol-lowering mainly statins and for triglyceride-lowering mainly fibrates are used. In primary and secondary prevention trials of heart disease they have shown to reduce the incidence of coronary artery disease or coronary events by 25-60 percent. Statins reduce mainly LDL-cholesterol levels by competitive inhibition of HMG-CoA reductase but have also shown to reduce fasting and postprandial triglyceride levels. Fibrates effectively reduce fasting and postprandial lipemia, shift the distribution of LDL particles towards less dense particles and increase HDL-cholesterol. Thus fibrates particularly address components of the metabolic syndrome and features of diabetic dyslipidemia. However studies still are needed showing definite evidence on differential therapy in lipid lowering based on prospective controlled trials with endpoints of macro- and microangiopathy in diabetic patients.

show abstract

“…Recent studies have shown excessive pp TG levels and an altered free fatty acid (FFA) metabolism to be early signs of metabolic abnormalities, leading to insulin resistance syndrome in obese subjects with normal fasting TGs and in atherosclerotic subjects without cholesterol abnormalities (12,13). In young, lean subjects and healthy offspring of diabetics, elevated pp TG levels were associated with insulin resistance, elevated proinsulin levels, increased intra-abdominal fat tissue and elevated pp thermogenesis and catecholamine and cortisol release, all of which are characteristic of MS (14)(15)(16). The distribution of pp TG maxima in these subjects followed a bimodal curve, suggesting the existence of a distinct subset of subjects with high pp TGs following a fatty meal and who exhibit the traits of MS (14).…”

Section: Introductionmentioning

confidence: 99%

Association of postprandial and fasting triglycerides with traits of the metabolic syndrome in the Metabolic Intervention Cohort Kiel

Rubin¹,

Helwig

Nothnagel³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Postprandial (pp) lipid metabolism is associated with insulin resistance and type 2 diabetes. In young men, pp triglycerides (TGs) are more strongly associated with traits of metabolic syndrome (MS) than fasting TGs. We established a cohort of middle-aged men selected for traits of MS and pp lipid metabolism to determine if fasting TGs or pp TGs are more closely related to MS. Research design and methods: A total of 1558 men were characterized for MS. A total of 755 men underwent an oral metabolic tolerance test consisting of a standardized high-fat meal and an oral glucose tolerance test. Blood samples were drawn in the fasting state and hourly until 9 h to determine pp TGs and free fatty acids. Glucose and insulin were analyzed until 5 h pp. Results: In the overall cohort, 329 subjects (21.1%) had a complete MS based on the Adult Treatment Panel III criteria, and 650 subjects (41.7%) had a complete MS based on the International Diabetes Federation criteria. The association of pp TGs with MS parameters was not stronger than the association of fasting TGs with them. Pp TGs were independently associated with b-cell function. Conclusions: Pp TGs did not show a higher correlation with MS traits than fasting TGs. This finding is probably due to the high incidence of overweight subjects in this middle-aged cohort.

show abstract

Prolonged Postprandial Increment in Triglycerides and Decreased Postprandial Response of Very Low Density Lipoproteins in Type 2 Diabetics following an Oral Lipid Load

Cited by 9 publications

References 20 publications

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis

Treatment of dyslipoproteinemia in the metabolic syndrome

Association of postprandial and fasting triglycerides with traits of the metabolic syndrome in the Metabolic Intervention Cohort Kiel

Contact Info

Product

Resources

About